Aggregator
对于需要血管内修复主动脉瘤的患者,全麻还是局部麻醉更好?
Cochrane is improving the way we manage and share the data associated with our reviews
At Cochrane, we aim to collaborate and create reliable synthesized evidence, making it accessible to all. We are dedicated to promoting access and the widest possible dissemination of our valuable evidence.
We're now making some big improvements to help continue that mission, by changing the way we share the data that is associated with Cochrane Reviews. Making data available to everyone is at the heart of our core principles. It opens opportunities for collaboration, reduces research waste, makes systematic reviewing more efficient, and ensures transparency and quality.
We are confident that these changes will improve the systematic review process by enabling easier re-use of data across Cochrane Reviews, meaning less time and effort being duplicated. It will also make it easier for users and decision-makers to access and examine the relevant data they need and use it to impact policy.
"I am confident that improving how we share data will appeal to our community of rigorous, passionate researchers. By embracing these new changes, we can to maximise the benefits from the investment in developing Cochrane Reviews, for both authors and users of our evidence .”
- Ella Flemyng, Cochrane Editorial Product Lead
“This is a really exciting milestone for Cochrane. This new data format facilitates data re-use, not only in RevMan but other tools too, such as Excel and different statistical packages. It also opens up opportunities for how we can use the data to innovate to best meet our stakeholder needs."
- Gert van Valkenhoef, Head of IT Development and Infrastructure
Summary:
- Cochrane is changing the way we share data in a bid to promote collaboration, reduce research waste and ensure quality by making Cochrane Review data more accessible.
- From 25 April, data associated with Cochrane Reviews can be downloaded from RevMan Web in standard formats, such as CSV and RIS.
- This new data package will include not only analysis data but also all other data associated with the Review related to the included studies, risk of bias assessments, and references.
- As Reviews with this data package are published, it will increase the impact of Cochrane’s Reviews and allow researchers, policymakers, practitioners and others to access and use Cochrane evidence more easily.
- We plan to continue making changes and improvements to pave the way for further innovation, with the potential to improve evidence and patient care.
What is changing?
From 25 April, changes to RevMan Web mean that authors will be able to download all available data files associated with a Cochrane Review in user-friendly formats like CSV and RIS. These downloadable files will include the Review's analyses data, along with other data associated with the Review - such as study characteristics, study data, risk of bias data and references. But that’s not all – once published, readers of the Cochrane Library will also be able to explore the data associated with the Review. All you have to do is select the 'Download statistical data' option on published Reviews and you'll have all the information you need at your fingertips.
Going forward, this data package will be available with new publications on the Cochrane Library under the same license as the associated Review (‘green’ or ‘gold’). This will of course be reassessed as part of Cochrane’s commitment to move to full open access by 2025.
For Cochrane Reviews published before this change, a conversion service will be available to convert the current downloadable RevMan 5 analyses files into the standard, easily reusable format.
What does it mean for you?
Authors: We believe these changes are good news for Cochrane authors because they mean that your published Reviews are going to have an even bigger impact. According to extensive research, sharing data leads to increased visibility, usage and impact of your research. This will help your hard work be seen and heard by everyone out there. We also know from our funders that better data sharing is increasingly becoming a key requirement in this area. And this way, RevMan automatically structures and organizes the data so you don’t have to.
Readers and end users: Unlocking data and information has now been made even easier for our users by our new shareable data. With our more streamlined and accessible Reviews, researchers, policymakers, practitioners and other user groups are now able to find the information they need to make impactful decisions.
What’s next?
With this new approach, we aim to make reusing Cochrane Reviews more efficient and effective. Our mission is to increase the visibility and discovery of research data, promote transparency and ensure our information and data can be reproduced. It is the start of Cochrane’s journey towards FAIR principles - Findability, Accessibility, Interoperability and Reuse - of data, which will open up new opportunities for how we can innovate with Cochrane evidence.
Further information:
- Data sharing editorial policy on the Cochrane Library
- Cochrane's FAQs on data sharing
- This is a fundamental step and is all about sharing reusable data so we can pave the way for improved evidence and patient care, as described in Cochrane’s Linked Data Project
预防前庭性偏头痛发作的非药物治疗效果如何?
气道清除技术与无气道清除技术治疗囊性纤维化的比较
早产儿动脉导管未闭的治疗
麦肯基方法对于治疗(亚)急性非特异性腰痛有效吗?
全身性阿片类药物对新生儿术后疼痛控制和管理的有效性和安全性如何?
阿片类药物以外的止痛药,用于治疗经受痛苦手术的婴儿的疼痛
与生理盐水溶液相比,雾化高渗盐水治疗婴儿急性细支气管炎的获益和风险是什么?
Featured Review: Experiences and perceptions of cash transfers for health
现金转账用于卫生的经验和看法
压力源对早产儿经鼻持续气道正压通气(CPAP)的影响
补充锌对于6个月至12岁儿童预防死亡和疾病以及促进生长是否有效?是否会造成不良影响?
糖尿病视网膜病变的血压控制
Featured Review: Methylphenidate for children and adolescents with ADHD
哌醋甲酯对患有注意力缺陷多动障碍(ADHD)的儿童和青少年是否有效?它是否会引起不良影响?
皮肤保留乳房切除术是治疗乳腺癌的安全有效的外科手术吗?
吸入性皮质类固醇与安慰剂治疗稳定型慢性阻塞性肺病(COPD)的比较
Chronic pain in children: time for change
On the 20th June 2019, Cochrane members published an overview review in the PAIN Journal on the efficacy of pharmacological interventions for children with chronic pain and cancer-related pain (https://bit.ly/2MMm5UH). The overview summarises the evidence from 23 systematic reviews, including several Cochrane Library reviews from our NIHR Programme Grant (https://papas.cochrane.org/nihr-programme-grant-2014-17). This work also builds on a policy workshop we held in 2018 focussing on this topic (https://bit.ly/2RGOGcK).
The overview highlights the lack of available evidence across all drugs aimed at relieving pain in children (just 6 trials of 393 participants). Therefore, we have launched a large dissemination plan to share these findings. We are publishing articles, blogs, newsletters, videos, and co-ordinating a social media campaign to help us start a conversation about the importance of evidence production in children’s pain.
We thank everyone who has contributed to this important piece of work. Please do feel free to use these links and distribute them widely to help us improve the science, policy and practice of paediatric pain management.
Resources
- Open access overview in PAIN: https://bit.ly/2MMm5UH and commentary via Ovid
- Cochrane Special Collection: https://bit.ly/2IM11ta
- Cochrane editorial: https://bit.ly/2YgN5N0
- Blogs on this evidence base (or its absence)
- Pharmacotherapy for treating chronic pain in children: A need for pragmatic idealism; Thomas 2020: https://doi.org/10.1111/pan.13781 (download pdf here)
- Body in Mind blog https://bit.ly/2Flwtwe
- The Conversation https://bit.ly/2YeBfmI (also shared on Yahoo News here; and IOL here; and MENAFN here)
- Evidently Cochrane https://bit.ly/2IPzerQ
- Press release from University of Bath https://bit.ly/2LjwLYp
- Supporting videos
- Dr Emma Fisher’s summary on YouTube https://bit.ly/2RDldjA
- University of Bath video summary https://twitter.com/UniofBath/status/1143800625764999169
- PAIN Journal Editor’s Pick video https://bit.ly/2X7HEUh
- Summary of the impact story so far (2019): https://bit.ly/2ITbzXz
- Key people to follow on Twitter (hashtag #timeforchange)
Other external links
- Somerset Live: Bath Hospital Trust supports study into drug treatment of chronic pain in children (here)
- Medical Xpress: Researchers reveal lack of evidence for drugs prescribed to treat chronic pain in children (here)
- News Medical (Life Sciences): Are Chronic Pain Relief Drugs for Children Effective? (here; also on Medicine News Line here; linked to via BioPortfolio here; and on herenciageneticayenfermedad here); and Study reveals lack of evidence for pediatric drugs prescribed to treat chronic pain (here)
- American News Report: Lack of evidence for drugs prescribed to treat chronic pain in children (here)
- EurekAlert: Researchers reveal lack of evidence for drugs prescribed to treat chronic pain in children (here)
- 7th Space: Researchers reveal lack of evidence for drugs prescribed to treat chronic pain in children (here)
- Newswise: Researchers reveal lack of evidence for drugs prescribed to treat chronic pain in children (here)
- Physical Therapy Products: Chronic Pain in Kids Needs to Be Studied More, Researchers Urge (here)
- The Independent: Children’s pain is under-researched (here - scroll down to end of page)
- Technology.org: Researchers reveal lack of evidence for drugs prescribed to treat chronic pain in children (here)
- BBC 1 West - BBC London News (here; here; here)
- BBC Bristol (here)
- Health Canal: Researchers reveal lack of evidence for drugs prescribed to treat chronic pain in children (here)
- Europa Press: in Spanish (here and here)
- The Courier & Advertiser Fife edition: Pain relief for children called into question (here - Press Reader account required)
- Health Medicine Network: Researchers reveal lack of evidence for drugs prescribed to treat chronic pain in children (here)
- ScienMag: Researchers Reveal Lack Of Evidence For Drugs Prescribed To Treat Chronic Pain In Children (here)
- Science Codex: Researchers reveal lack of evidence for drugs prescribed to treat chronic pain in children (here)
- Bioengineer.org: Researchers Reveal Lack Of Evidence For Drugs Prescribed To Treat Chronic Pain In Children (here)
- Bright Surf: Researchers reveal lack of evidence for drugs prescribed to treat chronic pain in children (here)
In 2020, Professor Christopher Eccleston, Dr Emma Fisher, and others produced The Lancet Child and Adolescent Health Commission’s report to address paediatric pain and recommend what more can be done to help children and young people: https://www.thelancet.com/commission/paediatric-pain
More links related to the Lancet launch in October 2020:
- Versus Arthritis news
- University of Bath press announcement
- The New York Times: Respecting Children’s Pain
- Artist Shaniah Barry - You can't see my pain
- Video Abstract: Delivering transformative action in paediatric pain
- The Lancet: Paediatric pain management in low-income and middle-income countries
- Follow on Twitter @LancetChildAdol
- Dalhousie University news
And continues...
In December 2020, the WHO published Guidelines on the management of chronic pain in children: access here.
Our Cochrane Reviews contributed to the guideline and Dr Emma Fisher led the review of effectiveness.
Overview (taken from the guideline)
In these guidelines, the World Health Organization (WHO) provides evidence-informed recommendations for the management of chronic pain in children. The recommendations are based on the most current, high-quality scientific evidence, and were formulated following processes and using methods that meet the highest international standards for guideline development. The recommendations in this guideline are based on systematic reviews of the evidence on benefits, harms, acceptability and feasibility, as well as on equity and resource considerations. The recommendations were formulated by the Guideline Development Group, consisting of individuals with diverse expertise and experiences and with global representation.
The purpose of this guideline is to assist WHO Member States and their partners in developing and implementing national and local policies, regulations, pain management protocols and best practices. It will help countries balance concerns about ensuring access to appropriate therapies for pain relief with the harms arising from misuse of medications and other potential adverse effects of interventions for pain management.
These guidelines focus on physical, psychological and pharmacological interventions for the management of primary and secondary chronic pain in children 0 to 19 years of age.
Wednesday, March 22, 2023